YIH
GSK icon

Y-Intercept (HK)’s GSK GSK Stock Holding History

Y-Intercept (HK)’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Sell
24,289
-24,875
-51% -$1.32M 0.03% 937
2026
Q1 		$2.71M Buy
+49,164
New +$2.66M 0.05% 576
2025
Q4 		– Sell
-5,589
Closed -$241K – 1716
2025
Q3 		$241K Sell
5,589
-17,250
-76% -$674K 0.01% 1437
2025
Q2 		$877K Buy
+22,839
New +$873K 0.02% 997
2024
Q4 		– Sell
-53,078
Closed -$2.17M – 1373
2024
Q3 		$2.17M Sell
53,078
-15,977
-23% -$654K 0.13% 188
2024
Q2 		$2.66M Buy
+69,055
New +$2.9M 0.15% 175
2024
Q1 		– Sell
-43,888
Closed -$1.63M – 1520
2023
Q4 		$1.63M Sell
43,888
-31,038
-41% -$1.11M 0.15% 182
2023
Q3 		$2.72M Buy
74,926
+45,943
+159% +$1.63M 0.27% 84
2023
Q2 		$1.03M Sell
28,983
-60,007
-67% -$2.15M 0.11% 282
2023
Q1 		$3.17M Buy
88,990
+52,456
+144% +$1.84M 0.37% 33
2022
Q4 		$1.28M Sell
36,534
-48,071
-57% -$1.6M 0.19% 137
2022
Q3 		$2.49M Buy
+84,605
New +$3.21M 0.25% 104
2022
Q1 		– Sell
-22,110
Closed -$1.22M – 809
2021
Q4 		$1.22M Buy
+22,110
New +$1.15M 0.29% 85
2021
Q3 		– Sell
-17,006
Closed -$846K – 751
2021
Q2 		$846K Buy
+17,006
New +$817K 0.22% 130

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Y-Intercept (HK)'s GSK Position: Q2 2026 in Review

Y-Intercept (HK) reduced its GSK (GSK) stake by 51% in Q2 2026, selling an estimated $1.32M and leaving 24,289 shares worth $1.27M. The position accounts for 0.03% of the portfolio, ranked #937.

Y-Intercept (HK) first reported a position in GSK in Q2 2021 and has held it in 14 quarters since. The position peaked at $3.17M in Q1 2023. 235 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Y-Intercept (HK) held 24,289 shares of GSK worth $1.27M as of Q2 2026.
  • Y-Intercept (HK) sold 24,875 GSK shares in Q2 2026, an estimated $1.32M.
  • GSK made up 0.03% of Y-Intercept (HK)'s portfolio in Q2 2026, its #937 holding.
  • Y-Intercept (HK) first reported a position in GSK in Q2 2021 and has held it in 14 quarters since.
  • Y-Intercept (HK)'s GSK position peaked at $3.17M in Q1 2023.
  • 235 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.